REPLIGEN CORP (RGEN) Stock Fundamental Analysis
USA - NASDAQ:RGEN - US7599161095 - Common Stock
124.38 USD
+4.99 (+4.18%)
124.38 USD
0 (0%)
RGEN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, there are worries on its profitability. While showing a medium growth rate, RGEN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
In the past year RGEN had a positive cash flow from operations.
Of the past 5 years RGEN 4 years were profitable.
RGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
RGEN's Return On Assets of -0.48% is in line compared to the rest of the industry. RGEN outperforms 60.00% of its industry peers.
RGEN's Return On Equity of -0.67% is fine compared to the rest of the industry. RGEN outperforms 61.82% of its industry peers.
RGEN has a Return On Invested Capital (0.57%) which is in line with its industry peers.
RGEN had an Average Return On Invested Capital over the past 3 years of 2.65%. This is significantly below the industry average of 15.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROIC | 0.57% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
With a Operating Margin value of 3.72%, RGEN perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
RGEN's Operating Margin has declined in the last couple of years.
RGEN has a Gross Margin (50.99%) which is comparable to the rest of the industry.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
RGEN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RGEN has more shares outstanding
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.65 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN has a better Altman-Z score (5.65) than 85.45% of its industry peers.
RGEN has a debt to FCF ratio of 5.04. This is a neutral value as RGEN would need 5.04 years to pay back of all of its debts.
RGEN has a better Debt to FCF ratio (5.04) than 69.09% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
RGEN's Debt to Equity ratio of 0.26 is in line compared to the rest of the industry. RGEN outperforms 50.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 5.65 |
ROIC/WACC0.06
WACC9.93%
2.3 Liquidity
A Current Ratio of 8.59 indicates that RGEN has no problem at all paying its short term obligations.
RGEN has a better Current ratio (8.59) than 89.09% of its industry peers.
A Quick Ratio of 7.32 indicates that RGEN has no problem at all paying its short term obligations.
The Quick ratio of RGEN (7.32) is better than 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 39.32% over the past year.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
Looking at the last year, RGEN shows a very negative growth in Revenue. The Revenue has decreased by -11.36% in the last year.
RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
3.2 Future
RGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.58% yearly.
Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.90% on average per year.
EPS Next Y16.2%
EPS Next 2Y22.73%
EPS Next 3Y24.82%
EPS Next 5Y26.58%
Revenue Next Year14.56%
Revenue Next 2Y14.12%
Revenue Next 3Y14.51%
Revenue Next 5Y15.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 76.31, the valuation of RGEN can be described as expensive.
RGEN's Price/Earnings ratio is in line with the industry average.
RGEN is valuated expensively when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 55.80, RGEN can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, RGEN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 76.31 | ||
| Fwd PE | 55.8 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 66.05 | ||
| EV/EBITDA | 51.95 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
RGEN's earnings are expected to grow with 24.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.71
PEG (5Y)10.74
EPS Next 2Y22.73%
EPS Next 3Y24.82%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
124.38
+4.99 (+4.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.6%
Inst Owner Change-11.04%
Ins Owners0.51%
Ins Owner Change-2.26%
Market Cap7.00B
Analysts80.71
Price Target183.05 (47.17%)
Short Float %6.9%
Short Ratio4.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.95%
Min EPS beat(2)-6.83%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)8.75%
Min EPS beat(4)-6.83%
Max EPS beat(4)25.89%
EPS beat(8)4
Avg EPS beat(8)7.57%
EPS beat(12)8
Avg EPS beat(12)8.61%
EPS beat(16)12
Avg EPS beat(16)12.23%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)1.23%
Max Revenue beat(2)2.15%
Revenue beat(4)2
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)2
Avg Revenue beat(8)-0.75%
Revenue beat(12)3
Avg Revenue beat(12)-0.94%
Revenue beat(16)7
Avg Revenue beat(16)0.86%
PT rev (1m)-0.31%
PT rev (3m)-2.26%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)4.34%
EPS NY rev (1m)0.35%
EPS NY rev (3m)0.64%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)3.55%
Revenue NY rev (1m)2.33%
Revenue NY rev (3m)2.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 76.31 | ||
| Fwd PE | 55.8 | ||
| P/S | 10.38 | ||
| P/FCF | 66.05 | ||
| P/OCF | 52.97 | ||
| P/B | 3.39 | ||
| P/tB | 12.92 | ||
| EV/EBITDA | 51.95 |
EPS(TTM)1.63
EY1.31%
EPS(NY)2.23
Fwd EY1.79%
FCF(TTM)1.88
FCFY1.51%
OCF(TTM)2.35
OCFY1.89%
SpS11.98
BVpS36.65
TBVpS9.63
PEG (NY)4.71
PEG (5Y)10.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.48% | ||
| ROE | -0.67% | ||
| ROCE | 0.9% | ||
| ROIC | 0.57% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 2.86% | ||
| OM | 3.72% | ||
| PM (TTM) | N/A | ||
| GM | 50.99% | ||
| FCFM | 15.72% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexcg growth 3Y-71.22%
ROICexcg growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score4
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 4.24 | ||
| Cap/Depr | 25.94% | ||
| Cap/Sales | 3.88% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 104.92% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.59 | ||
| Quick Ratio | 7.32 | ||
| Altman-Z | 5.65 |
F-Score4
WACC9.93%
ROIC/WACC0.06
Cap/Depr(3y)88.31%
Cap/Depr(5y)109.53%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.32%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%12.12%
EPS Next Y16.2%
EPS Next 2Y22.73%
EPS Next 3Y24.82%
EPS Next 5Y26.58%
Revenue 1Y (TTM)-11.36%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%18.36%
Revenue Next Year14.56%
Revenue Next 2Y14.12%
Revenue Next 3Y14.51%
Revenue Next 5Y15.9%
EBIT growth 1Y451.21%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year72.43%
EBIT Next 3Y40.62%
EBIT Next 5Y37.42%
FCF growth 1Y10.02%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-11.28%
OCF growth 3Y13.8%
OCF growth 5Y21.15%